Literature DB >> 3105450

Role of beta-lactamase in in vivo development of ceftazidime resistance in experimental Pseudomonas aeruginosa endocarditis.

A S Bayer, J Peters, T R Parr, L Chan, R E Hancock.   

Abstract

Two ceftazidime-resistant variants of Pseudomonas aeruginosa (PA-48, PA-60), obtained from cardiac vegetations of rabbits with endocarditis receiving ceftazidime therapy, were studied for mechanisms of resistance. Both resistant variants were stably derepressed for the type Id beta-lactamase, which was ceftazidime inducible in the parental strain (PA-96) used to initially infect the rabbits. There was no evidence of ceftazidime bioinactivation by the resistant strains, and their outer membrane permeabilities were comparable to those of the parental strain. No alterations were observed in patterns of outer membrane proteins or membrane lipopolysaccharides in the resistant variants as compared with the parental strain. Penicillin-binding protein patterns of the resistant variants revealed the absence of penicillin-binding protein 4 in both, with acquisition of a new protein of higher apparent molecular weight in PA-60. Calculation of the rate of appearance of ceftazidime in the periplasm at sub-MICs suggested that slow enzymatic hydrolysis of the beta-lactam, rather than nonhydrolytic trapping, was the major explanation for the induced resistance in vivo in strains PA-48 and PA-60.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3105450      PMCID: PMC174701          DOI: 10.1128/AAC.31.2.253

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  35 in total

1.  Outer membranes of gram-negative bacteria. XIX. Isolation from Pseudomonas aeruginosa PAO1 and use in reconstitution and definition of the permeability barrier.

Authors:  R E Hancock; H Nikaido
Journal:  J Bacteriol       Date:  1978-10       Impact factor: 3.490

2.  High resolution two-dimensional electrophoresis of proteins.

Authors:  P H O'Farrell
Journal:  J Biol Chem       Date:  1975-05-25       Impact factor: 5.157

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Outer membrane of Salmonella XIV. Reduced transmembrane diffusion rates in porin-deficient mutants.

Authors:  H Nikaido; S A Song; L Shaltiel; M Nurminen
Journal:  Biochem Biophys Res Commun       Date:  1976-05-23       Impact factor: 3.575

5.  Comparison of the beta-lactamase stability and the in-vitro activity of cefoperazone, cefotaxime, cefsulodin, ceftazidime, moxalactam and ceftriaxone against Pseudomonas aeruginosa.

Authors:  D M Livermore; R J Williams; J D Williams
Journal:  J Antimicrob Chemother       Date:  1981-10       Impact factor: 5.790

6.  Purification and properties of a binding protein for branched-chain amino acids in Pseudomonas aeruginosa.

Authors:  T Hoshino; M Kageyama
Journal:  J Bacteriol       Date:  1980-03       Impact factor: 3.490

7.  Comparative studies of penicillin-binding proteins in Pseudomonas aeruginosa and Escherichia coli.

Authors:  H Noguchi; M Matsuhashi; S Mitsuhashi
Journal:  Eur J Biochem       Date:  1979-10

8.  Properties of the penicillin-binding proteins of Escherichia coli K12,.

Authors:  B G Spratt
Journal:  Eur J Biochem       Date:  1977-01

9.  Efficacy of amikacin and ceftazidime in experimental aortic valve endocarditis due to Pseudomonas aeruginosa.

Authors:  A S Bayer; D Norman; K S Kim
Journal:  Antimicrob Agents Chemother       Date:  1985-12       Impact factor: 5.191

10.  Function of the outer membrane of Escherichia coli as a permeability barrier to beta-lactam antibiotics.

Authors:  W Zimmermann; A Rosselet
Journal:  Antimicrob Agents Chemother       Date:  1977-09       Impact factor: 5.191

View more
  8 in total

1.  Salt-resistant alpha-helical cationic antimicrobial peptides.

Authors:  C Friedrich; M G Scott; N Karunaratne; H Yan; R E Hancock
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

2.  Rapid method for determining the beta-lactamase-inducing potency of drugs.

Authors:  H Mett; I Oberkirch; B Schacher
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-10       Impact factor: 3.267

3.  In vitro evaluation of E1077, a new cephalosporin with a broad antibacterial spectrum.

Authors:  N Watanabe; R Hiruma; K Katsu
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

4.  Eradication of mucoid Pseudomonas aeruginosa with fluid liposome-encapsulated tobramycin in an animal model of chronic pulmonary infection.

Authors:  C Beaulac; S Clément-Major; J Hawari; J Lagacé
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

5.  Efficacy of ceftazidime and aztreonam alone or in combination with amikacin in experimental left-sided Pseudomonas aeruginosa endocarditis.

Authors:  A Pefanis; H Giamarellou; P Karayiannakos; I Donta
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

6.  Development of beta-lactam resistance and increased quinolone MICs during therapy of experimental Pseudomonas aeruginosa endocarditis.

Authors:  A S Bayer; L Hirano; J Yih
Journal:  Antimicrob Agents Chemother       Date:  1988-02       Impact factor: 5.191

7.  Bactericidal interactions of a beta-lactam and beta-lactamase inhibitors in experimental Pseudomonas aeruginosa endocarditis caused by a constitutive overproducer of type Id beta-lactamase.

Authors:  A S Bayer; M Selecky; K Babel; L Hirano; J Yih; T R Parr
Journal:  Antimicrob Agents Chemother       Date:  1987-11       Impact factor: 5.191

8.  Genetic characterization of TEM-type ESBL-associated antibacterial resistance in Enterobacteriaceae in a tertiary hospital in Ghana.

Authors:  Daniel Oduro-Mensah; Noah Obeng-Nkrumah; Evelyn Yayra Bonney; Ebenezer Oduro-Mensah; Kingsley Twum-Danso; Yaa Difie Osei; Sammy Tawiah Sackey
Journal:  Ann Clin Microbiol Antimicrob       Date:  2016-05-04       Impact factor: 3.944

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.